Overall Scope and Claims Analysis of U.S. Patent 10,584,113
Patent 10,584,113, titled "Methods for treating cancer with combination therapy," grants broad protection for a method involving administering a combination of a kinase inhibitor and immune checkpoint inhibitor to treat tumor conditions. The claims focus on specific compositions, dosages, and treatment protocols involving these agents in varied cancer types.
Scope of the Patent Claims
The patent's claims encompass:
- The use of specific kinase inhibitors, notably inhibitors of kinases such as VEGFR, PDGFR, or FGFR.
- Administration of immune checkpoint inhibitors, primarily anti-PD-1, anti-PD-L1, or anti-CTLA-4 antibodies.
- Combination therapy protocols, including sequential or concurrent administration.
- Treatment of specific cancers like melanoma, non-small cell lung cancer, renal cell carcinoma, among others.
- Dosage ranges, often specifying doses above a threshold to optimize therapeutic efficacy.
- Use of selected biomarkers to stratify patient populations.
The claims are designed to cover a broad spectrum of combination regimens. Claims extend to formulations and methods for specific treatment durations, dosing ratios, and patient populations. The structure of the claims suggests an intent to prevent infringement by minor modifications of administration protocols or drug compositions.
Claims Breakdown by Claim Type
| Claim Type |
Description |
Coverage |
Number of Claims |
| Composition Claims |
Cover specific combinations of kinase inhibitors with immune checkpoint antibodies |
Drugs, doses, and relative timing |
20+ |
| Method Claims |
Methods of administering combinations for treating cancer |
Treatment protocols, patient criteria |
~30 |
| Use Claims |
Use of specified compositions for particular indications |
Indications, biomarkers |
10+ |
| Formulation Claims |
Specific pharmaceutical formulations |
Delivery forms, carriers |
5+ |
Claims are predominantly method-based, which are usually easier to enforce and interpret. Composition and formulation claims supplement these, providing legal coverage for specific drug combinations and delivery methods.
Patent Landscape & Related Patents
The patent landscape reveals a crowded field involving combination therapies targeting immune checkpoints and kinase pathways. Important related patents include:
- US 10,420,513: Focuses on kinase inhibitors in combination with immunomodulators.
- WO 2018/084004: Covers immune checkpoint inhibitors with angiogenesis inhibitors.
- US 9,987,300: Encompasses combination therapy for various cancers using similar agents.
These patents indicate a competitive environment with overlapping claims, especially surrounding specific drug combinations and dosing strategies.
The patent family around 10,584,113 includes US and international filings, notably applications in Europe (EP) and China (CN). The family routes suggest expansion strategies to prevent global competition.
Patent Strengths and Vulnerabilities
Strengths:
- Broad claims covering multiple kinase and immune checkpoint inhibitors.
- Inclusion of multiple indications widens commercial applicability.
- Versatile treatment protocols.
Vulnerabilities:
- Prior art exists for combination therapies, especially in cancer immunotherapy (e.g., CheckMate trials).
- Narrower claims in some dependent claims may be circumvented through minor modifications.
- Method claims can be challenged if similar prior art exists showing obviousness.
Summary of Patent Durability
The patent is set to expire in 2038, assuming maintenance fee payments without extension. Its broad scope offers a competitive edge, but the crowded patent landscape and prior art risks could prompt challenges post-grant.
Key Takeaways
- U.S. Patent 10,584,113 protects a broad range of combination therapies involving kinase inhibitors and immune checkpoint blockade.
- The claims encompass both composition and methods, covering multiple treatment scenarios for cancer.
- The patent landscape is highly competitive with overlapping patents focusing on similar combination therapies.
- Its broad claims bolster potential market exclusivity but face vulnerability from prior art and obviousness challenges.
- Legal strategies will likely include defending claims through patent family extensions and potentially narrowing claims via continuations or divisional applications.
FAQs
Q1: Does the patent cover specific drugs or classes?
A: It covers broad classes of kinase inhibitors and immune checkpoint inhibitors, including specific agents like PD-1 and PD-L1 antibodies.
Q2: What are the main cancer types targeted by the patent?
A: Melanoma, non-small cell lung cancer, renal cell carcinoma, and other solid tumors.
Q3: Can minor changes to dosing or administration avoid infringement?
A: Possibly, as some claims specify parameters that could be circumvented by modifying the protocols or drug compositions.
Q4: How does this patent compare to prior art?
A: It builds upon existing combination therapy patents but claims broader protection; however, prior art demonstrates similar therapeutic combinations.
Q5: Will the patent face invalidation challenges?
A: Challenges are probable due to prior art, especially if analogous combination therapies have been disclosed or tested before the priority date.
References
[1] Title and abstract from USPTO.
[2] Related patents and patent applications (US 10,420,513; WO 2018/084004; US 9,987,300).
[3] Public cancer therapy trial data and related patent literature.
